

16 January 2024

ASX Market Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By electronic lodgement

Dear Ms Kostopoulos,

Micro-X Limited (MX1) – Appendix 3Y Late Lodgement Notice

Please find attached an Appendix 3Y “Change of Director’s Interest Notice” for Mr Peter Rowland relating to the lapse of Performance Rights held by Mr Rowland in August and November 2023.

In relation to the late lodgement of the Appendix 3Y, I advise as follows:

1. The Appendix 3Y is being lodged late due to an administrative oversight. As soon as the oversight was identified, the documents were prepared and lodged with ASX.
2. Micro-X Limited and the directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B. The late lodgement is due to an administrative oversight in the Company Secretary office.
3. Micro-X Limited believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

Yours sincerely



Kingsley Hall
Chief Executive Officer
Micro-X Limited

This ASX announcement is authorised by Kingsley Hall, the Company Secretary of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: www.micro-x.com

CONTACTS

Micro-X Limited	Investor Enquiries
<p>Kingsley Hall, Chief Executive Officer Rebecca Puddy, Head of Corporate Communications Tel: +61 8 7099 3966 E: media@micro-x.com</p>	<p>David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com</p>

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Micro-X Limited
ABN	21 153 273 735

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Robin Rowland
Date of last notice	13 July 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Rosemary Rowland (spouse of Peter Rowland) Peter Robin Rowland & Rosemary Louise Rowland as trustees for <Montecampione Superannuation Fund>
Date of change	30 November 2023
No. of securities held prior to change	<u>Direct</u> 13,534,068 Fully Paid Ordinary Shares 1,597,800 Unlisted Performance Rights <u>Indirect</u> 475,000 Fully Paid Ordinary Shares – Rosemary Rowland 570,279 Fully Paid Ordinary Shares - Peter Robin Rowland & Rosemary Louise Rowland as trustees for <Montecampione Superannuation Fund> 200 Unlisted Convertible Notes - Peter Robin Rowland & Rosemary Louise Rowland as trustees for <Montecampione Superannuation Fund>
Class	Unlisted Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	N/A
Number disposed	715,460
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	<p><u>Direct</u> 13,534,068 Fully Paid Ordinary Shares</p> <p>882,340 Unlisted Performance Rights</p> <p><u>Indirect</u> 475,000 Fully Paid Ordinary Shares – Rosemary Rowland</p> <p>570,279 Fully Paid Ordinary Shares - Peter Robin Rowland & Rosemary Louise Rowland as trustees for <Montecampione Superannuation Fund></p> <p>200 Unlisted Convertible Notes - Peter Robin Rowland & Rosemary Louise Rowland as trustees for <Montecampione Superannuation Fund></p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Vesting criteria not met in full.</p> <p>560,336 STI Performance Rights lapsed 31 August 2023</p> <p>155,124 LTI Performance Rights lapsed 30 November 2023</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.